• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Comparative study of concentrated blood derivatives of factor VIII].

作者信息

Baklaja R, Miletić V, Stajić M, Cvetković V, Grozdanić V

出版信息

Bilt Hematol Transfuz. 1984;12(2):91-103.

PMID:6441567
Abstract

The work presents results of the investigations of blood derivatives--F VIII concentrates: commercial cryoprecipitate, concentrate of intermediary purity and derivatives of high purity: Kriobulin--Immuno, Octobulin--Landerlan, Profilate--Alfa, Factor VIII--Behring, Hemofil--Hyland, Factorate--Armour Pharma, AHF--Kaote Cutter. The following parameters were investigated: VIII: C, VIIIR: Ag, total protein, protein electrophoresis, IgG, IgA and IgM immunoglobulins and anti-A and anti-B isoagglutinins. All derivatives except cyroprecipitate have considerably higher VIIIR: RAg value compared with VIII: C, which indicated inactivation of labile VIII: C component during concentrate preparation. Specific activity varied depending on purity of preparations, but ranged from 1,72 to 22. High isoagglutinin titer of anti-A was noted in preparations of high purity, as well as the presence of immunoglobulins. Despite considerable differences in vitro, all concentrated derivatives F VIII have similar immediate clinical effect and recovery from 0,87 to 1,36. All results indicate that new ways of derivative F VIII purification should be found with lower degree of contamination of other plasma proteins and less risk of hepatitis virus transmission. When certain indications are recognized, cryoprecipitate produced in our country in all blood transfusion services should be used.

摘要

相似文献

1
[Comparative study of concentrated blood derivatives of factor VIII].
Bilt Hematol Transfuz. 1984;12(2):91-103.
2
Characteristics of the factor VIII protein and Factor XIII in various factor VIII concentrates.各种凝血因子 VIII 浓缩物中凝血因子 VIII 蛋白和凝血因子 XIII 的特性
Scand J Haematol. 1980 Apr;24(4):340-9. doi: 10.1111/j.1600-0609.1980.tb01593.x.
3
[Comparative protein chemistry studies on Factor VIII concentrates].
Arzneimittelforschung. 1984;34(8):895-900.
4
Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Arzneimittelforschung. 1989 Oct;39(10):1302-5.
5
Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.两种血管性血友病因子浓缩物[Biostate和AHF(高纯度)]在血管性血友病患者中的药代动力学比较。一项随机交叉、多中心研究。
Thromb Haemost. 2007 Jun;97(6):922-30.
6
Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates.市售病毒灭活凝血因子VIII浓缩物的生化特性及体内特性
Eur J Haematol. 1988 Mar;40(3):205-14. doi: 10.1111/j.1600-0609.1988.tb00825.x.
7
[Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].[冷沉淀中病毒热灭活过程中的凝血因子 VIII:C 活性]
Lijec Vjesn. 1990 Jul-Aug;112(7-8):212-5.
8
Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.临床中间纯度凝血因子VIII浓缩物生产过程中凝血因子VIII复合物活性的变化
Thromb Haemost. 1981 Oct;46(3):597-601.
9
A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.三种凝血因子 VIII/血管性血友病因子浓缩物的多实验室比较评估
Thromb Haemost. 2002 Mar;87(3):466-76.
10
Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.血友病和血管性血友病浓缩物治疗的发展与现状
Wien Klin Wochenschr. 1982 Oct 15;94(19):509-14.